ANX Mast Therapeutics, Inc.

SAN DIEGO, Feb. 28 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical company developing anticancer and antiviral therapies, announced today that Brian M. Culley, chief business officer and senior vice president of business development, will present a corporate overview on Wednesday, March 7 at 11:30 am at BIO-Europe Spring 2007. BIO-Europe Spring is a partnering conference for the biotechnology industry that will feature one-on-one partnering meetings and company presentations. The conference will be held March 5-7 at the Milano Convention Centre in Milan, Italy. More information on the conference can be found at http://www.ebdgroup.com/bes/index.htm. About ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing anticancer and antiviral therapies that improve the performance and safety of existing treatments by addressing significant problems, such as drug metabolism, toxicity, bioavailability and resistance. The Company's lead product candidate, ANX-510, or CoFactor, is in Phase III and Phase II(b) clinical trials for the treatment of patients with metastatic colorectal cancer, as well as a Phase II clinical trial for the treatment of patients with advanced breast cancer. More information can be found on the Company's web site at http://www.adventrx.com/. Forward Looking Statement ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors that, if they do not materialize or prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual results to differ materially include, but are not limited to: uncertainties inherent in the drug development process; the timing and success of clinical trials; the validity of research results; the receipt of necessary approvals from the FDA and other regulatory agencies; and other risks and uncertainties more fully described in ADVENTRX's press releases and public filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov/. ADVENTRX does not intend to update any forward-looking statement, including as set forth in this press release, to reflect events or circumstances arising after the date on which it was made. DATASOURCE: ADVENTRX Pharmaceuticals, Inc. CONTACT: Media, Amy Martini, +1-212-301-7223 for WeissComm Partners; or Investors, Ioana C. Hone, +1-858-552-0866 for ADVENTRX Pharmaceuticals Web site: http://www.adventrx.com/ http://www.ebdgroup.com/bes/index.htm Company News On-Call: http://www.prnewswire.com/gh/cnoc/comp/920134.html

Copyright